Studies how genetic changes affect thinking and behavior in Parkinson's disease
Follows adults with Parkinson's disease over 5 years, comparing those with and without genetic changes.
Key facts
- Who runs it
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes
- Status
- Recruiting
- People taking part
- 68 people, planned
- Started
- 14 Dec 2021
- Expected to end
- 14 Dec 2031
- Type of study
- Observational, 2 groups
- Treatments tested
- Clinical examinations and clinical scales administration
- Record updated
- 26 March 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Parkinson's disease who take dopaminergic medicine and have had genetic testing for inherited forms of the disease.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Diagnosed Parkinson's disease
- Earlier treatment
- Must be taking dopaminergic medicine (L-Dopa and/or dopamine agonists). People who had Deep Brain Stimulation (DBS) cannot join.
- Biomarker or test result
- Genetic testing for Mendelian (inherited) forms of Parkinson's disease
Main reasons for not taking part
- Had Deep Brain Stimulation (DBS) treatment
- Cannot give informed consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- diagnosed with Parkinson's Disease (PD)
- in use of dopaminergic medication (L-Dopa and/or dopamine agonists)
- genetic testing for mendelian forms of PD
- able to provide informed consent to participate in the study
Who cannot take part
- Patients underwent Deep Brain Stimulation (DBS) treatment
Where in Italy
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyContact: Francesca MameliTaking people
About the trial
What the trial wants to find out
The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD.
Read full original descriptionShow less
The goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in PD patients.
Patients will be assessed over time using test, questionnaire and standardised clinica scales. An initial assessment and annual follow-up assessments will be carried out for 5 years.
Researchers will compare data collected from patients with genetic mutation versus patients without mutation.
The 2 groups in the trial
- Experimental group
Parkinson's Disease patients with genetic mutation
Treatment: Clinical examinations and clinical scales administration
- Control group
Parkinson's Disease patients without genetic mutation
Treatment: Clinical examinations and clinical scales administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes in Patients Undergoing Dopaminergic Treatment
- Plain-language title
- Studies how genetic changes affect thinking and behavior in Parkinson's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 March 2024